Dennis W.T. Nilsen

Prof. Dr. Dennis W.T. Nilsen

Department of Clinical Science, University of Bergen, Bergen, Hordaland, Norway
+1
orcid

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 1996 in Circulation
Verified
Journal Article
Closed access
TOTorbjørn Omland
Torbjørn Omland
AAAsbjørn Aakvaag
Asbjørn Aakvaag
VBVernon V. S. Bonarjee
Vernon V. S. Bonarjee
KCKenneth Caidahl
Kenneth Caidahl
RLRolv Terje Lie
Rolv Terje Lie
KDKenneth Dickstein
Kenneth Dickstein
Background Elevated plasma levels of atrial natriuretic peptide (ANP) and the N-terminal fragment of the ANP prohormone (N-ANP) are associated with decreased left ventricular function and decreased long-term survival after acute myocardial infarction (AMI). Previous data suggest that plasma brain natriuretic peptide (BNP) may increase proportionally more than plasma ANP after AMI and in chronic heart failure. The diagnostic and prognostic value of plasma BNP as an indicator of left ventricular dysfunction and long-term survival after AMI, relative to that of ANP and N-ANP, remain to be established. Methods and Results Venous blood samples for analysis of ANP, N-ANP, and BNP were obtained on day 3 after symptom onset from 131 patients with documented AMI. Left ventricular ejection fraction was determined by echocardiography in a subsample of 79 patients. Twenty-eight cardiovascular and 3 noncardiovascular deaths occurred during the follow-up period (median, 1293 days). All three peptides proved to be powerful predictors of cardiovascular mortality by univariate Cox proportional hazards regression analyses (ANP: P <.0001; N-ANP: P =.0002; BNP: P <.0001). In a multivariate model, plasma BNP ( P =.021) but not ANP ( P =.638) or N-ANP ( P =.782) provided additional prognostic information beyond left ventricular ejection fraction. Logistic regression analysis showed that ANP ( P =.003) and N-ANP ( P =.027) but not BNP ( P =.14) were significantly associated with a left ventricular ejection fraction ≤45%. Conclusions These results suggest that plasma BNP determination provides important, independent prognostic information after AMI. Although plasma ANP appears to be a better predictor of left ventricular dysfunction, plasma BNP may have greater potential to complement standard prognostic indicators used in risk stratification after AMI because of its strong, independent association with long-term survival, enhanced in vitro stability, and simplicity of analysis.

9 February 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
AKAre Annesønn Kalstad
Are Annesønn Kalstad
Peder MyhrePeder Myhre
Peder Myhre
KLKristian Laake
Kristian Laake
STSjur Hansen Tveit
Sjur Hansen Tveit
ESErik Berg Schmidt
Erik Berg Schmidt
OIOn behalf of the OMEMI Investigators
On behalf of the OMEMI Investigators
Background: High intake of marine n-3 polyunsaturated fatty acids (PUFA) has been associated with reduced risk of cardiovascular events; however, this has not been confirmed in patients with a recent acute myocardial infarction (AMI). Elderly patients are at particularly increased cardiovascular risk after myocardial infarction, but few trials address this group specifically. Omega-3 fatty acids hold the potential to reduce cardiovascular events with limited adverse effects in this vulnerable group. The hypothesis was that daily addition of 1.8g n-3 PUFA to standard of care secondary prophylaxis in elderly patients who have survived an AMI would reduce the risk of subsequent cardiovascular events during 2 years follow-up. Methods: The OMEMI trial (Omega-3 Fatty acids in Elderly with Myocardial Infarction) is an investigator-initiated, multicenter, randomized clinical trial adding 1.8 g n-3 PUFA (930 mg eicosapentaenoic acid and 660 mg docosohexaenoic acid) versus placebo (corn oil) daily to standard of care in patients aged 70 to 82 years with recent (2–8 weeks) AMI. The primary endpoint was a composite of nonfatal AMI, unscheduled revascularization, stroke, all-cause death, heart failure hospitalization after 2 years. The secondary outcome was new atrial fibrillation. The safety outcome was major bleeding. Serum fatty acids were measured as biomarkers of adherence. Results: In total, 1027 patients were randomized. Follow-up data were available for 1014 patients who were included in the intention-to-treat analysis. Mean±SD age was 75±3.6 years, 294 (29%) were female, and mean triglycerides were 111.4±61.9 mg/dL. The primary endpoint occurred in 108 (21.4%) patients on n-3 PUFA versus 102 (20.0%) on placebo (hazard ratio, 1.08 [95% CI, 0.82–1.41]; P =0.60). The secondary endpoint occurred in 28 (7.2%) patients on n-3 PUFA versus 15 (4.0%) on placebo (1.84 [0.98–3.45]; P =0.06). Median changes in eicosapentaenoic acid and docosahexaenoic acid were +87% and +16% for n-3 PUFA versus −13% and −8% for placebo. Major bleeding occurred in 54 (10.7%) and 56 (11.0%) in the n-3 PUFA and placebo groups, respectively ( P =0.87). Similar results were found in per-protocol analysis (n=893). Conclusions: We could not detect reduction in clinical events in our elderly patients with recent AMI who were treated with 1.8 g n-3 PUFAs daily for 2 years. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01841944.

1 July 2001 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
DNDennis W.T. Nilsen
Dennis W.T. Nilsen
GAGrethe Albrektsen
Grethe Albrektsen
KLKnud Landmark
Knud Landmark
SMSolfrid Moen
Solfrid Moen
TATorbjørn Aarsland
Torbjørn Aarsland
LWLeik Woie
Leik Woie
Background: Results of epidemiologic studies and clinical trials indicate that moderate doses of n−3 fatty acids reduce the risk of cardiovascular disease and may improve prognosis. Objective: The objective was to evaluate the effect of a high-dose ethylester concentrate of n−3 fatty acids administered early after an acute myocardial infarction (MI) on subsequent cardiac events and serum lipids. Design: Three hundred patients with acute MI were randomly assigned to a daily dose of either 4 g highly concentrated n−3 fatty acids or corn oil, administered in a double-blind manner over 12–24 mo. Median follow-up time was 1.5 y. Clinical follow-up, including the drawing of blood samples, was performed after 6 wk of treatment and later at 0.5-year intervals. Results: Forty-two (28%) patients in the n−3 group and 36 (24%) in the corn oil group experienced at least one cardiac event (cardiac death, resuscitation, recurrent MI, or unstable angina). No significant difference in prognosis was observed between groups for single or combined cardiac events. Total cholesterol concentrations decreased in both groups, with no significant intergroup differences. On average, the monthly increase in HDL cholesterol was 1.11% in the n−3 group and 0.55% in the corn oil group (P = 0.0016). Triacylglycerol concentrations decreased by 1.30%/mo in the n−3 group, whereas they increased by 0.35%/mo in the corn oil group (P < 0.0001). Conclusion: No clinical benefit of a high-dose concentrate of n−3 fatty acids compared with corn oil was found despite a favorable effect on serum lipids.

1 December 2007 in Resuscitation
Verified
Journal Article
Closed access
ALAlf Inge Larsen
Alf Inge Larsen
ÅHÅshild S. Hjørnevik
Åshild S. Hjørnevik
CEChristian Lycke Ellingsen
Christian Lycke Ellingsen
DNDennis W.T. Nilsen
Dennis W.T. Nilsen

1 March 2013 in The American Journal of Cardiology
Verified
Journal Article
Closed access
ALAlf Inge Larsen
Alf Inge Larsen
DNDennis W.T. Nilsen
Dennis W.T. Nilsen
JYJennifer Yu
Jennifer Yu
RMRoxana Mehran
Roxana Mehran
ENEugenia Nikolsky
Eugenia Nikolsky
GSGregg W. Stone
Gregg W. Stone

1 November 2003 in Pathophysiology of Haemostasis and Thrombosis
Verified
Journal Article
Closed access
HGHeidi Grundt
Heidi Grundt
DNDennis W.T. Nilsen
Dennis W.T. Nilsen
MMMohammad A. Mansoor
Mohammad A. Mansoor
ØHØyvind Hetland
Øyvind Hetland
ANArne Nordøy
Arne Nordøy
We hypothesized that n–3 polyunsaturated fatty acids (n–3 PUFAs) as compared to corn oil administered for 1 year following an acute myocardial infarction (MI) may reduce plasma total homocysteine (p-tHcy), ultrasensitive C-reactive protein (µCRP), and the adhesive properties of the endothelium, expressed as soluble E-selectin (sE-selectin) and soluble intercellular adhesion molecule-1 (sICAM-1). In a prospective, randomised, double-blind study, 300 acute MI patients were allocated to highly concentrated n–3 PUFAs (n = 150) or corn oil (n = 150). After 1 year on treatment there was an intergroup difference in p-tHcy in favour of the n–3 group (n = 118), p = 0.022. However, sE-selectin, sICAM-1 and µCRP were unaffected by the treatment. In conclusion, reduction of p-tHcy by long-term n–3 PUFAs treatment was not associated with demonstrable effects on markers of endothelial adhesion properties.